**ABSTRACT**

**Objective:** To evaluate the efficacy and tolerability of open-label pimavanserin in patients with Parkinson's disease psychosis (PDP) who continued treatment with pimavanserin 34 mg for 4 weeks after a 6-week randomized controlled study (Core Study).

**Methods:** Patients completed a 6-week double-blind Core Study (NCT01174004), followed by an open-label extension (OLE) for up to 10 weeks. Mean (SE) SAPS-PD scores decreased from Core Study baseline to OLE Week 4 with pimavanserin in those on Core Study placebo (P<0.0001) and a similar duration of treatment with pimavanserin 34 mg.

**Results:** Mean (SE) SAPS H+D scores decreased from Core Study baseline to OLE Week 4 with pimavanserin in those on Core Study placebo (P<0.0001) and a similar duration of treatment with pimavanserin 34 mg.

**Conclusion:** Open-label treatment with pimavanserin 34 mg for 4 weeks after a 6-week Core Study was safe and effective for PDP.}

---

**RESULTS (CONT.)**

**CONCLUSIONS**

**Improved efficacy and tolerability of open-label pimavanserin for 4 weeks after a 6-week randomized controlled study (Core Study) was safe and effective for PDP.**

---

**DISCUSSION**

**ACKNOWLEDGMENTS**

**REFERENCES**

**DISCLOSURES**

**ACKNOWLEDGMENTS**

**REFERENCES**

**DISCLOSURES**

**ACKNOWLEDGMENTS**

**REFERENCES**

**DISCLOSURES**

**ACKNOWLEDGMENTS**

**REFERENCES**

**DISCLOSURES**

**ACKNOWLEDGMENTS**

**REFERENCES**

**DISCLOSURES**